Tatjana Stankovic

Accepting PhD Students

PhD projects

Tatjana Stankovic’s research is focused on an elucidation of the role of ataxia telangiectasia mutated (ATM) and other DNA damage response genes in the multistep process of leukaemia/ lymphomagenesis. Particular emphasis is given to DNA damage response defects that can be targeted for tumour-specific treatment. Therefore, a long-term goal is to translate the understanding of DNA damage response pathways in haematopoietic malignancies into novel therapeutic strategies. Current and future studies focus on:

Identification of a network of ATM-dependent cellular responses and DNA repair defects that can be targeted for treatment in chronic leukaemia
Addressing different mechanisms of tumorigenesis and novel therapeutic approaches in mouse models of ATM-deficient haematopoietic malignancies
Studying the effect of histone deacetylase (HDAC) inhibitors and demethylating agents on immune responses in acute myeloid leukaemia (AML)
Identifying activated kinases and DNA repair proteins that cause chemoresistance in paediatric acute lymphoblastic leukaemia (ALL)

Research activity per year

If you made any changes in Pure these will be visible here soon.

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

Fingerprint

Dive into the research topics where Tatjana Stankovic is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

1 Similar Profiles

70 Article
5 Conference contribution
4 Comment/debate
4 Letter
More

SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response
Bland, P., Saville, H., Wai, P. T., Curnow, L., Muirhead, G., Nieminuszczy, J., Ravindran, N., John, M. B., Hedayat, S., Barker, H. E., Wright, J., Yu, L., Mavrommati, I., Read, A., Peck, B., Allen, M., Gazinska, P., Pemberton, H. N., Gulati, A., Nash, S., & 19 othersNoor, F., Guppy, N., Roxanis, I., Pratt, G., Oldreive, C., Stankovic, T., Barlow, S., Kalirai, H., Coupland, S. E., Broderick, R., Alsafadi, S., Houy, A., Stern, M-H., Pettit, S., Choudhary, J. S., Haider, S., Niedzwiedz, W., Lord, C. J. & Natrajan, R., Aug 2023, In: Nature Genetics. 55, 8, p. 1311-1323 13 p.
Research output: Contribution to journal › Article › peer-review

Open Access
File
21 Downloads (Pure)
ATM germline variants in a young adult with chronic lymphocytic leukemia: 8 years of genomic evolution
Royo, R., Magnano, L., Delgado, J., Ruiz-Gil, S., Gelpí, J. L., Heyn, H., Taylor, M. A., Stankovic, T., Puente, X. S., Nadeu, F. & Campo, E., 7 Jun 2022, In: Blood Cancer Journal. 12, 6, 4 p., 90.
Research output: Contribution to journal › Letter › peer-review

Open Access
File

12 Downloads (Pure)
Correction: ATM germline variants in a young adult with chronic lymphocytic leukemia: 8 years of genomic evolution
Royo, R., Magnano, L., Delgado, J., Ruiz-Gil, S., Gelpí, J. L., Heyn, H., Taylor, M. A., Stankovic, T., Puente, X. S., Nadeu, F. & Campo, E., 6 Dec 2022, In: Blood Cancer Journal. 12, 12, 1 p., 163.
Research output: Contribution to journal › Comment/debate › peer-review

Open Access
Linking epigenome regulation with DNA repair
Stankovic, T. & Kwok, M., 9 Jun 2022, In: Blood. 139, 23, p. 3356-3357 2 p.
Research output: Contribution to journal › Comment/debate › peer-review
Signatures of TOP1 transcription-associated mutagenesis in cancer and germline
The Genomics England Research Consortium & Colorectal Cancer Domain UK 100,000 Genomes Project, 24 Feb 2022, In: Nature. 602, 7898, p. 623-631 9 p.
Research output: Contribution to journal › Article › peer-review

Open Access
File
35 Downloads (Pure)

4 Active
31 Finished

Novel biomarkers for PARP inhibitor trials for children with cancer
Stankovic, T., Beggs, A. & Gatz, S.
Little Princess Trust
1/02/21 → 31/01/24
Project: Research
Defining genomic, pharmacological and microenvironmental contexts in which to target a protein hydroxylase
Stankovic, T., Coleman, M. & Tennant, D.
Cancer Research Uk
1/09/20 → 31/12/24
Project: Research
Utilising a synthetic lethality approach to specifically target ATM deficient tumours
Stankovic, T., Davies, N. & Stewart, G.
Cancer Research Uk
1/09/20 → 31/08/24
Project: Research
RNaseH2 inactivation in cancer cells: a pathogenic mechanism and therapeutic target
Stankovic, T., Moss, P., Stewart, G. & Taylor, M.
Cancer Research Uk
1/01/20 → 31/12/25
Project: Research
Targeting DDR defects in CLL as a model disease
Stankovic, T.
ASTRA ZENECA UK LIMITED
1/01/19 → 1/08/21
Project: Research

Tatjana Stankovic

Personal profile

Expertise related to UN Sustainable Development Goals

Fingerprint

Collaborations and top research areas from the last five years

Dive into details

SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response

ATM germline variants in a young adult with chronic lymphocytic leukemia: 8 years of genomic evolution

Correction: ATM germline variants in a young adult with chronic lymphocytic leukemia: 8 years of genomic evolution

Linking epigenome regulation with DNA repair

Signatures of TOP1 transcription-associated mutagenesis in cancer and germline

Novel biomarkers for PARP inhibitor trials for children with cancer

Defining genomic, pharmacological and microenvironmental contexts in which to target a protein hydroxylase

Utilising a synthetic lethality approach to specifically target ATM deficient tumours

RNaseH2 inactivation in cancer cells: a pathogenic mechanism and therapeutic target

Targeting DDR defects in CLL as a model disease

Tatjana Stankovic

Personal profile

Expertise related to UN Sustainable Development Goals

Fingerprint

Collaborations and top research areas from the last five years

Research output

Projects